Physician profile
Brent Videau
NPI 1730189192
$5,816.09
in general payments reported to CMS, 2019-2025
34 companies · $498 in 2025
The $498 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $788 · 2020: $406 · 2021: $484 · 2022: $1,703 · 2023: $1,051 · 2024: $886 · 2025: $498.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,336 · Education: $98.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,335.62 |
| Education | $98.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,364.23 | 2020-2024 | Thoratec Heartmate 3 Lvas Implant Kit |
| Boston Scientific Corporation | $690.43 | 2019-2024 | Watchman Access System, Watchman Flx |
| E.R. Squibb & Sons, L.L.C. | $689.33 | 2019-2024 | Camzyos, Eliquis |
| Cvrx, INC. | $270.23 | 2023-2025 | Barostim Neo System |
| Merck Sharp & Dohme LLC | $233.94 | 2024-2025 | Verquvo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $229.39 | 2019-2025 | Jardiance |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $214.52 | 2019-2025 | Lifevest |
| Amgen INC. | $170.89 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $170.21 | 2022-2025 | |
| Janssen Pharmaceuticals, INC | $160.83 | 2019-2024 | Xarelto |
| Esperion Therapeutics, INC. | $158.37 | 2020-2024 | Nexletol |
| Actelion Pharmaceuticals US, INC. | $157.98 | 2019-2025 | Uptravi, Opsumit |
| Novartis Pharmaceuticals Corporation | $145.72 | 2019-2023 | |
| Abiomed | $145.69 | 2023 | Impella |
| Impulse Dynamics (USA) INC. | $143.89 | 2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $110.12 | 2023-2025 | Hillrom - Carnation Ambulatory Monitor |
| Medtronic Vascular, INC. | $93.10 | 2019 | |
| Heartflow, INC. | $80.74 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $79.62 | 2019-2024 | Evkeeza |
| Philips North America LLC | $78.28 | 2023-2025 | Mcot |
| Bayer Healthcare Pharmaceuticals INC. | $75.06 | 2022-2025 | |
| Lexicon Pharmaceuticals, INC. | $65.80 | 2024 | |
| Kowa Pharmaceuticals America, INC. | $52.92 | 2019 | |
| Gilead Sciences, INC. | $45.78 | 2019 | |
| Sanofi-Aventis U.S. LLC | $39.88 | 2019 | |
| Lantheus Medical Imaging, INC. | $30.16 | 2025 | |
| Arbor Pharmaceuticals, INC. | $25.48 | 2019 | |
| Kiniksa Pharmaceuticals International, Plc | $21.64 | 2024 | Arcalyst |
| Kestra Medical Technology Services, INC. | $19.71 | 2024 | Assure Wcd |
| Alnylam Pharmaceuticals INC. | $19.06 | 2025 | Amvuttra |
| Amarin Pharma, INC. | $17.43 | 2021 | |
| Elutia, INC. | $15.66 | 2023 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brent Videau listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.